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Imbalanced rates of apoptosis have
been proposed to create a platform that
is necessary and sufficient for tumor for-
mation (Green and Evan, 2002). The
host environment can influence cancer
outgrowth by altering tumor gene
expression, resulting in tumor prolifera-
tion and suppression of the endogenous
apoptotic program. Fas and Fas ligand
(FasL) are an interacting, extracellular
proapoptotic receptor/ligand pair (re-
viewed in Nagata, 1999). Trimerization of
membrane bound Fas with FasL causes
recruitment of the FADD adaptor protein
and procaspase-8, the key initiator cas-
pase in the death receptor pathway.
Procaspase-8 is activated by induced
proximity and further activates down-
stream caspases and initiates cleavage
of critical apoptotic substrates. Active
caspase-8 also engages the intrinsic
mitochondrial pathway of apoptosis
through the cleavage of Bid, which
translocates to the mitochondria and
promotes release of cytochrome c.
The role of Fas-induced apoptosis in
the maintenance of immune homeostasis
is well established (Nagata, 1999). More
recently, Fas-induced apoptosis has been
implicated in the control of tumor progres-
sion and chemotherapeutic drug-induced
death. Functional Fas is highly expressed
on a variety of nonmalignant tissues,
while Fas loss-of-function commonly
accompanies the malignant phenotype.
Multiple molecular mechanisms underlie
Fas loss-of-function in cancer including
downregulation of transmembrane Fas
by promoter methylation (reviewed in
Owen-Schaub et al., 2000), transcrip-
tional repression (Ivanov et al., 2001),
histone acetylation (Maecker et al.,
2000), and alternative mRNA splicing to
produce soluble Fas protein lacking a
transmembrane anchor (reviewed in
Owen-Schaub et al., 2000). Overexpres-
sion of the degenerate caspase homolog
c-FLIP (Bullani et al., 2001) and inacti-
vating Fas mutations (reviewed in Owen-
Schaub et al., 2000) have also been
shown to contribute to Fas loss-of-func-
tion in nonhematopoietic cancers. In sev-
eral cancer types, Fas loss-of-function
has been shown to track with an aggres-
sive disease presentation and de-
creased patient survival. In experimental
animal models (reviewed in Owen-
Schaub et al., 2000), disruption of Fas
has been shown to result in enhanced
tumor development while Fas restoration
has been shown to delay primary tumor
outgrowth. The acquired ability to spread
and metastasize represents the most
intractable feature of cancer. Recent
studies have implicated Fas and FasL
interactions in the control of distant
metastases (Owen-Schaub et al., 1998)
as well as in the development of
chemotherapeutic resistance in some
cell types (reviewed in Johnstone et al.,
2002). These observations suggest that
Fas is a frequent target for inactivation
during oncogenesis and that Fas-
induced apoptosis plays a crucial role in
the biology and response of malignant
disease.
Both transmembrane and cleaved
FasL can induce Fas clustering and initi-
ate apoptotic cell death (Nagata, 1999).
Although some nonhematopoietic tissues
(retinal pigment epithelial cells and lung
epithelial cells, for example) display FasL,
expression is most prominent in bone
marrow-derived immune cells including
activated lymphocytes, neutrophils, nat-
ural killer (NK) cells, and macrophages.
Conceivably, FasL+ immune effectors
could inhibit Fas+ tumor survival by direct
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Recent studies have provided evidence that Fas and FasL interactions are important in the control of malignant disease
and that changes in the level of Fas expression can determine immune escape and therapeutic responses.
Figure 1. Model for Fas loss-of-function in
tumor progression
This model is supported by the findings of
Maecker et al. (2002) that Fas is important for
NK cell-mediated immune surveillance and
chemosensitivity.
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cytotoxicity and/or release of proinflam-
matory cytokines leading to increased
cellular infiltration.Tumor immune escape
has been implicated in disease progres-
sion following Fas loss-of-function in sev-
eral experimental models (reviewed in
Owen-Schaub et al., 2000). Recently, an
intriguing study (Screpanti et al., 2001)
implicated NK cells in the rejection of
tumors through the death receptor path-
way.These results raise the exciting pos-
sibility that immune surveillance result-
ing in NK cell-mediated tumor rejection
could be accomplished through the
upregulation of functional, transmem-
brane-anchored Fas in advanced tumors
where Fas loss-of-function has occurred
(Figure 1). Evidence for this exciting pos-
sibility is presented in studies by
Maecker et al. (2002) in this issue of
Cancer Cell.
Using mouse embryo fibroblasts
(MEF cells), these investigators docu-
ment that early-passage MEF cells con-
taining wild-type p53 express high levels
of Fas (equivalent to that observed in
early transformed cells or benign
tumors). On the other hand, p53 null
MEF cells express low levels of Fas, con-
sistent with previous reports that wild-
type p53 can transcriptionally activate
Fas and increase export of this protein to
the surface (reviewed in Owen-Schaub
et al., 2000). Late-passage, wild-type
p53-containing MEF cells downregulate
Fas expression to undetectable levels,
paralleling findings observed in highly
malignant cells in tumor progression
models (Figure 1). Late-passage MEF
can be induced to express high levels of
functional Fas following infection with a
retroviral vector containing Fas or treat-
ment with the histone deacetylase
inhibitor, Trichostatin A (TSA), to relieve
Fas repression via an acetylation-depen-
dent mechanism (Maecker et al., 2000).
Using this model system, Maecker et al.
(2002) has now provided direct evidence
that changes in Fas levels can determine
immune escape of transformed cells and
influence responses to chemotherapeu-
tic agents in vivo. In initial tumorigenecity
studies, early-passage MEF (expressing
high levels of functional Fas) were shown
to be weakly tumorigenic, whereas late-
passage MEF (expressing low levels of
functional Fas) were shown to be highly
tumorigenic in SCID animals (containing
NK cells). When high levels of Fas were
induced on late-passage MEF by retro-
viral Fas or treatment with TSA, local
tumor growth was potently inhibited
compared to late-passage, Fas-deficient
MEF containing vector alone, a receptor
control, or a dominant-negative Fas.
These studies identify Fas as an impor-
tant death receptor restricting local
tumor outgrowth; however, they do not
examine potential underlying effector
mechanisms. In the next set of experi-
ments, early- and late-passage MEF
(expressing high and low Fas levels,
respectively) were injected into SCID
beige mice (lacking NK cells), and
tumorigenecity was examined. In the
absence of NK cells, early- and late-
passage MEF formed local tumors at
equivalent rates, implying a role for NK
cells as the underlying effector mecha-
nism restricting Fas+ tumor growth in
SCID mice. While encouraging as a
potential therapeutic approach, it
remained to be determined whether Fas
upregulation could inhibit growth of
established tumors in a more clinically
relevant model. To this end, the investi-
gators injected late-passage, Fas-defi-
cient MEF in the subcutis of SCID ani-
mals and waited for 10 days to allow
tumor establishment. After such time,
tumors were treated with TSA or TSA in
combination with the chemotherapeutic
drug etoposide and the effects on tumor
growth measured. In this model, TSA
alone had little effect on growth, sug-
gesting that Fas restoration in estab-
lished tumors may be ineffective as a
single agent. However, when TSA was
used in combination with etoposide,
tumor growth was potently inhibited. The
effects of the combination treatment
were NK cell dependent and indepen-
dent of MHC class I changes in the
tumor. These findings raise the exciting
possibility that Fas upregulation in com-
bination with other agents such as radia-
tion and chemotherapy may be particu-
larly effective in the treatment of estab-
lished tumors. The strict dependence on
NK cells for the elimination of “early” Fas+
MEF tumors in TSA alone treatment
groups and “late” Fas+ MEF tumors in the
TSA- and etoposide-treated group is
intriguing and argues that increasing
Fas levels may be a useful strategy to
enhance immune-mediated clearance of
tumors and reverse chemoresistance in
some tumor types. It will be especially
interesting to determine whether such
therapeutic approaches are effective in
the treatment of spontaneous, syngene-
ic tumors and to characterize the poten-
tial involvement of additional FasL+
immune effectors (lymphocytes, neu-
trophils, macrophages) in immunocom-
petent animals. Understanding how
apoptosis is silenced in the malignant
cell and how apoptotic pathways can be
restored is tantamount to designing
more effective cancer therapies and pre-
venting tumor progression.
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